Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Acrivon Therapeutics, Inc. Common Stock ACRV NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
57/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$21.83
+1231.1%

Acrivon Therapeutics, Inc. Common Stock (ACRV) is a Biotechnology company in the Healthcare sector, currently trading at $1.64. It has a SharesGrow Score of 56/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is ACRV = $22 (+1231.1% upside).

Valuation: ACRV trades at a trailing Price-to-Earnings (P/E) of -0.7 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.07.

Net income is $78M (loss), growing at -44.5%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $3M against $113M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 7.69 (strong liquidity). Debt-to-assets is 2.1%. Total assets: $130M.

Analyst outlook: 9 / 10 analysts rate ACRV as buy (90%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

$21.83
▲ 1231.1% Upside
Average Price Target
Based on 10 Wall Street analysts offering 12-month price targets for Acrivon Therapeutics, Inc. Common Stock, the average price target is $21.83, with a high forecast of $30.00, and a low forecast of $17.00.
Highest Price Target
$30.00
Average Price Target
$21.83
Lowest Price Target
$17.00

ACRV SharesGrow Score Overview

69/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ACRV

✓
VALUE Pass
100/100
ACRV trades at a trailing Price-to-Earnings (P/E) of -0.7 (S&P 500 average ~25). Forward PEG 0.07 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $22, implying +1241.5% from the current price $2. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
ACRV: +0%/yr revenue is, -44.5%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet ACRV: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 7.69 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
ACRV: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 9 / 10 analysts rate ACRV as buy (90%). Analyst consensus target is $22 (+1241.5% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1.05-3.56
Volume334.46K
Avg Volume (30D)843K
Market Cap$51.75M
Beta (1Y)1.74
Share Statistics
EPS (TTM)-2.02
Shares Outstanding$38.51M
IPO Date2022-11-15
Employees75
CEOPeter Blume-Jensen
Financial Highlights & Ratios
Gross Profit$-1.36M
EBITDA$-82.76M
Net Income$-77.91M
Operating Income$-84.11M
Total Cash$118.58M
Total Debt$2.71M
Net Debt$-38.79M
Total Assets$129.72M
Price / Earnings (P/E)-0.8
Analyst Forecast
1Y Price Target$20.00
Target High$30.00
Target Low$17.00
Upside+1,119.5%
Rating ConsensusBuy
Analysts Covering10
Buy 90% Hold 10% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS0048901096

Price Chart

Track all markets on TradingView
ACRV
Acrivon Therapeutics, Inc. Common Stock ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
1.05 52WK RANGE 3.56

People Also View

OPT
OPT
Opthea Limited
$3.41
+1.49%
 ANAB
ANAB
AnaptysBio, Inc.
$70.22
+2.17%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$27.32
+0.59%
 RZLT
RZLT
Rezolute, Inc.
$3.56
-1.36%
 MOLN
MOLN
Molecular Partners AG
$4.14
-1.66%
 ADAG
ADAG
Adagene Inc.
$3.81
-0.78%
 ANTX
ANTX
AN2 Therapeutics, Inc.
$2.98
-1.00%
 PMVP
PMVP
PMV Pharmaceuticals, Inc.
$1.47
+8.89%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message